TITLE:
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

CONDITION:
Cervical Cancer

INTERVENTION:
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years

SUMMARY:

      The purpose of the study is to determine if an investigational vaccine with a single
      component develops an immune response that is similar to the equivalent investigational
      vaccine with four components to reduce cervical disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 16 Years to 23 Years
Criteria:

        Inclusion Criteria:

          -  Female with an intact uterus with lifetime history of 0-4 sexual partners

        Exclusion Criteria:

          -  Prior Human Papillomavirus Vaccine (HPV) vaccination;

          -  Prior abnormal paps;

          -  Prior history of genital warts
      
